Back to Clinical Trials

Brief Title: Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer

INTRODUCTION

  • Org Study ID: IMMU-132-13
  • Secondary ID: 2020-002964-29
  • NTC ID: NCT04527991
  • Sponsor: Gilead Sciences
Gilead Clinical Trials Website

BRIEF SUMMARY

The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).

  • Overall Status
    Recruiting
  • Start Date
    January 13, 2021
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Overall Survival (OS)

Primary Outcome 1 - Timeframe: Up to 3.5 years

CONDITION

  • Locally Advanced or Metastatic Unresectable Urothelial Cancer

ELIGIBILITY

Key Inclusion Criteria:
Individuals with histologically documented metastatic or locally advanced unresectable UC defined as
Tumor (T) 4b, any node (N) or

- Any T, N 2-3 Tumors of upper and lower urinary tract are permitted. Mixed histologic types are allowed if urothelial is the predominant histology.

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
Individuals with progression or recurrence following receipt of platinum-containing regimen and anti programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) therapy for metastatic or locally advanced unresectable disease will be enrolled.
a. Individuals with recurrence or progression ≤12 months following completion of cisplatin-containing chemotherapy given in the neo-adjuvant/adjuvant setting may utilize that line of therapy to be eligible for the study. The 12-month period is counted from completion of surgical intervention or platinum therapy, respectively. These individuals must receive anti PD-1/PD-L1 therapy in the metastatic or locally advanced unresectable setting to be eligible.

- b. Individuals who received either carboplatin or anti PD-1/PD-L1 therapy in the neo- adjuvant/adjuvant setting will not be able to count that line of therapy towards eligibility for the study.
c. Cisplatin ineligible individuals who meet one of the below criteria and who were treated with carboplatin in the metastatic or locally advanced unresectable settings may count that line of therapy towards eligibility. They must then have received anti PD-1/PD-L1 therapy in metastatic or locally advanced unresectable setting to be eligible for the study.
Cisplatin ineligibility is defined as meeting one of the following criteria:
1. Creatinine Clearance < 60 mL/min - 2. Grade ≥ 2 Audiometric Hearing Loss - 3. Grade ≥ 2 Peripheral Neuropathy - 4. New York Heart Association (NYHA) Class III heart failure - 5. ECOG PS ≥ 2 - d. Anti PD-1/PD-L1 therapy administered as part of maintenance therapy may be counted towards eligibility for the study - e. Individuals who have progressed after receiving enfortumab vedotin in prior lines of therapy, and individuals who are either ineligible or unable to tolerate enfortumab vedotin therapy, are eligible to enroll in the study - f. Individuals who received only concurrent chemoradiation for bladder preservation without further systemic therapy are not eligible to enroll in the study. The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen and no progression was noted prior to the change in platinum. - Individuals with previously treated brain metastases may participate in the study provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and stabilization of all neurologic symptoms, have no evidence of new or enlarging brain metastases, and are not using steroids >20 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to first dose of the study drug.

- Adequate hematologic counts without transfusion or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥1,500/mm^3, and platelets ≥100,000/µL).
Adequate hepatic function (bilirubin ≤1.5x institutional upper limit of normal (IULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin >3 g/dL).
Docetaxel will only be option in TPC arm for Individuals with a total bilirubin ≤1 x IULN, and an AST and/or ALT ≤1.5x IULN if alkaline phosphatase is also >2.5 x IULN.
Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation or other validated instruments (e.g. Modification of Diet in Renal Disease (MDRD) equation).

- Females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

- Females of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study drug. Individuals of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >2 years.

- Males must agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy.
Key Exclusion Criteria:
Females who are pregnant or lactating.

- Have had a prior anti-cancer monoclonal antibody (mAb)/ antibody-drug conjugate (ADC) within 4 weeks prior to Cycle 1 Day 1 (C1D1) or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to C1D1. Individuals participating in observational studies are eligible.

- Have received prior chemotherapy for UC with any available SOC therapies in the control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions where vinflunine is approved and is commercially available).
Have not recovered (i.e., ≤ Grade 1) from AEs due to previously administered chemotherapeutic agent.
Note: Individuals with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study.

- Note: If Individuals received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy.

- Have previously received topoisomerase 1 inhibitors.
Have an active second malignancy.
• Note: Individuals with a history of malignancy that have been completely treated and with no evidence of active cancer for 3 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence are allowed to enroll in the study after discussion with the medical monitor.
Have active cardiac disease, defined as:
Myocardial infarction or unstable angina pectoris within 6 months of C1D1.

- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.

- NYHA Class III or greater congestive heart failure or left ventricular ejection fraction of <40%. - Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal (GI) perforation within 6 months of enrollment. - Have an active serious infection requiring anti-infective therapy (Contact medical monitor for clarification). - Have known history of Human Immunodeficiency Virus (HIV)-1/2 with undetectable viral load and on medications that may interfere with SN-38 metabolism. - Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In individuals with a history of HBV or HCV, individuals with a detectable viral load will be excluded. - Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations. - Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab govitecan-hziy or unable or unwilling to receive the doses specified in the protocol. - Have inability to complete all specified study procedures for any reason.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Gilead Study Director

Role: Study Director

Affiliation: Gilead Sciences

Overall Contact

Name: Gilead Study Director

Phone: 1-833-445-3230(GILEAD-0)

Email: GileadClinicalTrials@gilead.com

LOCATION

Facility Status Contact
Facility: Mayo Clinic - Arizona
Phoenix, Arizona 85054
United States
Status: Recruiting Contact: N/A
Facility: UCLA Hematology/ Oncology
Los Angeles, California 90095
United States
Status: Recruiting Contact: N/A
Facility: University of California Irvine (UCIMC)
Orange, California 92868
United States
Status: Recruiting Contact: N/A
Facility: MedStar Washington Hospital Center
Washington, District of Columbia 20010
United States
Status: Recruiting Contact: N/A
Facility: Baptist MD Anderson Cancer Center
Jacksonville, Florida 32207
United States
Status: Recruiting Contact: N/A
Facility: Boca Raton Clinical Research Global USA - Plantation
Plantation, Florida 33322
United States
Status: Recruiting Contact: N/A
Facility: University of Iowa Hospitals and Clinics
Iowa City, Iowa 52242
United States
Status: Recruiting Contact: N/A
Facility: University of Maryland School of Medicine
Baltimore, Maryland 21201
United States
Status: Recruiting Contact: N/A
Facility: Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
United States
Status: Recruiting Contact: N/A
Facility: Montefiore Medical Center
Bronx, New York 10467
United States
Status: Recruiting Contact: N/A
Facility: Roswell Park Cancer Institute
Buffalo, New York 14263
United States
Status: Recruiting Contact: N/A
Facility: Weill Cornell Medical College
New York, New York 10065
United States
Status: Recruiting Contact: N/A
Facility: Cleveland Clinic
Cleveland, Ohio 44195
United States
Status: Recruiting Contact: N/A
Facility: Oklahoma Cancer Specialists and Research Institute (OCSRI)
Tulsa, Oklahoma 74104
United States
Status: Recruiting Contact: N/A
Facility: Penn State Hershey Cancer Institute
Hershey, Pennsylvania 17033
United States
Status: Recruiting Contact: N/A
Facility: Thompson Oncology Group - Knoxville Downtown
Knoxville, Tennessee 37916
United States
Status: Recruiting Contact: N/A
Facility: University Cancer Specialists - Knoxville
Knoxville, Tennessee 37920
United States
Status: Recruiting Contact: N/A
Facility: Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas 75390
United States
Status: Recruiting Contact: N/A
Facility: Center for Cancer and Blood Disorders
Fort Worth, Texas 76104
United States
Status: Recruiting Contact: N/A
Facility: Seattle Cancer Care Alliance (SCCA)
Seattle, Washington 98109
United States
Status: Recruiting Contact: N/A
Facility: Summit Cancer Centers
Spokane, Washington 99208
United States
Status: Recruiting Contact: N/A
Facility: Calvary Mater Newcastle
Waratah, New South Wales 2298
Australia
Status: Recruiting Contact: N/A
Facility: Westmead Hospital
Westmead, New South Wales 2145
Australia
Status: Recruiting Contact: N/A
Facility: Icon Cancer Centre Wesley
Auchenflower, Queensland 4066
Australia
Status: Recruiting Contact: N/A
Facility: Southern Adelaide Local Health Network Incorporated
Bedford Park, South Australia 5042
Australia
Status: Recruiting Contact: N/A
Facility: Ashford Cancer Centre Research - ICON Cancer Centre Adelaide
Kurralta Park, South Australia 5037
Australia
Status: Recruiting Contact: N/A
Facility: ICON Cancer Centre Hobart
Hobart, Tasmania 7001
Australia
Status: Recruiting Contact: N/A
Facility: Monash Health
Clayton, Victoria 3168
Australia
Status: Recruiting Contact: N/A
Facility: Austin Health
Heidelberg, Victoria 3084
Australia
Status: Recruiting Contact: N/A
Facility: Peter MacCallum Cancer Centre
Melbourne, Victoria 3000
Australia
Status: Recruiting Contact: N/A
Facility: Sunshine Hospital
Saint Albans, Victoria 3021
Australia
Status: Recruiting Contact: N/A
Facility: Liverpool Hospital
Nedlands, Western Australia 6009
Australia
Status: Recruiting Contact: N/A
Facility: Sir Charles Gairdner Hospital
Nedlands, Western Australia 6009
Australia
Status: Recruiting Contact: N/A
Facility: Az Maria Middelares Ghent
Gent, 9000
Belgium
Status: Recruiting Contact: N/A
Facility: Universitair Ziekenhuis Gent
Gent, 9000
Belgium
Status: Recruiting Contact: N/A
Facility: Universitair Ziekenhuis Leuven
Leuven, 3000
Belgium
Status: Recruiting Contact: N/A
Facility: Centre Hospitalier Universitaire de Liège
Liège, B-4000
Belgium
Status: Recruiting Contact: N/A
Facility: Specialized Hospital for Active Treatment of Oncological Diseases - Sofia District
Sofia, 1233
Bulgaria
Status: Recruiting Contact: N/A
Facility: qeii health sciences centre - VG site
Halifax, B3H 2Y9
Canada
Status: Recruiting Contact: N/A
Facility: Juravinski Hospital and Cancer Centre
Hamilton, L8V 5C2
Canada
Status: Recruiting Contact: N/A
Facility: London Health Sciences Centre
London, N6A 4G5
Canada
Status: Recruiting Contact: N/A
Facility: McGill University Health Centre
Montréal, H4A 3J1
Canada
Status: Recruiting Contact: N/A
Facility: Princess Margaret Cancer Centre
Toronto, M5G 2M9
Canada
Status: Recruiting Contact: N/A
Facility: British Columbia Cancer Agency-Vancouver Centre
Vancouver, V5Z 4E6
Canada
Status: Recruiting Contact: N/A
Facility: Peking University First Hospital
Beijing, 100034
China
Status: Recruiting Contact: N/A
Facility: Chinese People's Liberation Army General Hospital - 301 Hospital
Beijing, 100039
China
Status: Recruiting Contact: N/A
Facility: Beijing Cancer Hospital
Beijing, 100142
China
Status: Recruiting Contact: N/A
Facility: Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Chengdu Shi, 610072
China
Status: Recruiting Contact: N/A
Facility: Chongqing University Cancer Hospital
Chongqing, 400030
China
Status: Recruiting Contact: N/A
Facility: The First Affiliated Hospital of Fujian Medical University
Fujian, 350005
China
Status: Recruiting Contact: N/A
Facility: Sun Yat-Sen University Cancer Center
Guangzhou Shi, 510060
China
Status: Recruiting Contact: N/A
Facility: Zhejiang Provincial People's Hospital - Zhaohui
Hangzhou, 310014
China
Status: Recruiting Contact: N/A
Facility: Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital
Hangzhou, 310022
China
Status: Recruiting Contact: N/A
Facility: Anhui Provincial Cancer Hospital
Hefei, 230031
China
Status: Recruiting Contact: N/A
Facility: Qilu Hospital of Shandong University
Jinan Shi, 250012
China
Status: Recruiting Contact: N/A
Facility: The First Affiliated Hospital of Nanchang University
Nanchang City, 330006
China
Status: Recruiting Contact: N/A
Facility: Nanjing Drum Tower Hospital
Nanjing, 210008
China
Status: Recruiting Contact: N/A
Facility: Liaoning Cancer Hospital and Institute
Shenyang, 110042
China
Status: Recruiting Contact: N/A
Facility: Tianjin Medical University Cancer Institute & Hospital
Tianjin, 300060
China
Status: Recruiting Contact: N/A
Facility: Affiliated Tumor Hospital of Xinjiang Medical University
Urumqi, 830000
China
Status: Recruiting Contact: N/A
Facility: The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, 325000
China
Status: Recruiting Contact: N/A
Facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan City, 430030
China
Status: Recruiting Contact: N/A
Facility: Institut de Cancérologie de l'Ouest
Angers, 33075
France
Status: Recruiting Contact: N/A
Facility: Ramsay Health Clinic Belharra
Bayonne, 29200
France
Status: Recruiting Contact: N/A
Facility: CHU Saint Andre
Bordeaux, 14076
France
Status: Recruiting Contact: N/A
Facility: Centre Hospiltalier Universitaire Brest - Hôpital Morvan
Brest, 63011
France
Status: Recruiting Contact: N/A
Facility: Centre Georges- Francois Leclerc
Dijon, 69373
France
Status: Recruiting Contact: N/A
Facility: Centre Antoine Lacassagne
Nice Cedex 2, 75015
France
Status: Recruiting Contact: N/A
Facility: Centre Hospitalier Universitaire de Nimes
Nimes, 35042
France
Status: Recruiting Contact: N/A
Facility: Hôpital Européen Georges-Pompidou
Paris, 35760
France
Status: Recruiting Contact: N/A
Facility: Centre Eugene Marquis
Rennes Cedex, 67091
France
Status: Recruiting Contact: N/A
Facility: Centre Hospitalier Privé Saint-Grégoire
Saint-Grégoire, 92150
France
Status: Recruiting Contact: N/A
Facility: Les Hôpitaux Universitaires de Strasbourg
Strasbourg cedex, 31059
France
Status: Recruiting Contact: N/A
Facility: Hôpital Foch
Suresnes, 94805
France
Status: Recruiting Contact: N/A
Facility: Institut Claudius Regaud
Toulouse Cedex 9, 6000
France
Status: Recruiting Contact: N/A
Facility: Institut Gustave Roussy
Villejuif Cedex, 0114
France
Status: Recruiting Contact: N/A
Facility: New Hospitals
Tbilisi, 0160
Georgia
Status: Recruiting Contact: N/A
Facility: Evex Medical corporation
Tbilisi, 60389
Georgia
Status: Recruiting Contact: N/A
Facility: Centrum fur Hamatologie und Onkologie Bethanien
Frankfurt/Main, 56068
Germany
Status: Recruiting Contact: N/A
Facility: Asklepios Klinik Altona
Hamburg, 48149
Germany
Status: Recruiting Contact: N/A
Facility: Institut Für Versorgungsforschung in Der Onkologie
Koblenz, 72622
Germany
Status: Recruiting Contact: N/A
Facility: Universitatsklinikum Munster
Münster, 72076
Germany
Status: Recruiting Contact: N/A
Facility: Studienpraxis Urologie
Nürtingen, 115 26
Germany
Status: Recruiting Contact: N/A
Facility: Universitätsklinikum Tübingen
Tübingen, 546 22
Germany
Status: Recruiting Contact: N/A
Facility: Bioclinic - Thessaloniki
Thessaloniki, 555 35
Greece
Status: Recruiting Contact: N/A
Facility: Anassa General Clinic
Thessaloniki, 3109601
Greece
Status: Recruiting Contact: N/A
Facility: Queen Mary Hospital
Hong Kong, 44281
Hong Kong
Status: Recruiting Contact: N/A
Facility: Hong Kong United Oncology Centre
Kowloon, 52621
Hong Kong
Status: Recruiting Contact: N/A
Facility: Shamir Medical Center (Assaf Harofeh)
Be'er Ya'akov, 52100
Israel
Status: Recruiting Contact: N/A
Facility: Rambam Health Care Campus
Haifa, 70124
Israel
Status: Recruiting Contact: N/A
Facility: Hadassah University Hospital Ein Kerem
Jerusalem, 16132
Israel
Status: Recruiting Contact: N/A
Facility: Meir Medical Center
Kfar-Sava, 47014
Israel
Status: Recruiting Contact: N/A
Facility: Sheba Medical Center
Tel Hashomer, 20132
Israel
Status: Recruiting Contact: N/A
Facility: Ospedale Policlinico San Martino
Genova, 38122
Italy
Status: Recruiting Contact: N/A
Facility: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, 37126
Italy
Status: Recruiting Contact: N/A
Facility: Azienda Ospedaliera Santa Maria di Terni
Terni, 35015
Italy
Status: Recruiting Contact: N/A
Facility: Ospedale di Trento - Presidio Ospedaliero Santa Chiara
Trento, 10408
Italy
Status: Recruiting Contact: N/A
Facility: Pusan National University Hospital
Busan-si, 13620
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Chungbuk National University Hospital
Cheongju-city, 03080
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Chungnam National University Hospital
Daejeon, 03722
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: National Cancer Center
Goyang-si, 05505
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Pusan National University Yangsan Hospital
Gyeongsangnam-do, 06351
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Gachon University Gil Medical Center
Incheon, 137-040
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Seoul National University Bundang Hospital
Seongnam-si, 16247
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Seoul National University Hospital
Seoul, 4710-243
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Severance Hospital, Yonsei University Health System
Seoul, 6300-858
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Asan Medical Center
Seoul, 2410-197
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Samsung Medical Center
Seoul, 1649-035
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: The Catholic University of Korea Seoul Saint Mary's Hospital
Seoul, 5000
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: The Catholic University of Korea Saint Vincent's Hospital
Suwon, 00907
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria
Lisbon, 08035
Portugal
Status: Recruiting Contact: N/A
Facility: Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E
Porto, 8036
Portugal
Status: Recruiting Contact: N/A
Facility: BRCR Medical Center, Inc
San Juan, 28034
Puerto Rico
Status: Recruiting Contact: N/A
Facility: Icon Cancer Centre Farrer Park
Singapore, 08243
Singapore
Status: Recruiting Contact: N/A
Facility: Tan Tock Seng Hospital
Singapore, 31008
Singapore
Status: Recruiting Contact: N/A
Facility: Hospital del Mar - Parc de Salut
Barcelona, 39008
Spain
Status: Recruiting Contact: N/A
Facility: Hospital Universitari Vall D'Hebron
Barcelona, 41013
Spain
Status: Recruiting Contact: N/A
Facility: Hospital Clinic de Barcelona
Barcelona, 553 05
Spain
Status: Recruiting Contact: N/A
Facility: MD Anderson Cancer Center
Madrid, 581 85
Spain
Status: Recruiting Contact: N/A
Facility: Hospital Universitario Ramon y Cajal
Madrid, 171 76
Spain
Status: Recruiting Contact: N/A
Facility: Hospital Sant Joan de Déu de Manresa
Manresa, 4051
Spain
Status: Recruiting Contact: N/A
Facility: Clinica Universidad de Navarra
Pamplona, 6500
Spain
Status: Recruiting Contact: N/A
Facility: Hospital Universitario Marqués de Valdecilla
Santander, 3010
Spain
Status: Recruiting Contact: N/A
Facility: Hospital Universitario Virgen del Rocio
Sevilla, 813
Spain
Status: Recruiting Contact: N/A
Facility: Universitetssjukhuset i Linköping
Linköping, 11217
Sweden
Status: Recruiting Contact: N/A
Facility: Karolinska Universitetssjukhuset - Solna
Stockholm, 333
Sweden
Status: Recruiting Contact: N/A
Facility: University of Bern
Bern, W1G 6AD
Switzerland
Status: Recruiting Contact: N/A
Facility: Kaohsiung Veterans General Hospital
Kaohsiung, M20 4BX
Taiwan
Status: Recruiting Contact: N/A
Facility: China Medical University Hospital
Taichung City, OX3 7LE
Taiwan
Status: Recruiting Contact: N/A
Facility: Taipei Veterans General Hospital
Taipei City, PR2 9HT
Taiwan
Status: Recruiting Contact: N/A
Facility: Chang Gung Memorial Hospital - Linkou Branch
Taoyuan, SM2 5PT
Taiwan
Status: Recruiting Contact: N/A
Facility: Barts Health NHS Trust
London,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Sarah Cannon Research Institute LondonSarah Cannon Research Institute London
London,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Oxford University Hospitals NHS Foundation Trust
Oxford,
United Kingdom
Status: Recruiting Contact: N/A
Facility: The Royal Marsden NHS Foundation Trust
Surrey,
United Kingdom
Status: Recruiting Contact: N/A
Facility: The Royal Wolverhampton NHS Trust
Wolverhampton,
United Kingdom
Status: Recruiting Contact: N/A